- Home
- KNOP vs CRGX Comparison
KNOP vs CRGX Comparison
Compare KNOP & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- CRGX
- Stock Information
- Founded
- KNOP 2013
- CRGX 2021
- Country
- KNOP United Kingdom
- CRGX United States
- Employees
- KNOP N/A
- CRGX N/A
- Industry
- KNOP Marine Transportation
- CRGX
- Sector
- KNOP Consumer Discretionary
- CRGX
- Exchange
- KNOP Nasdaq
- CRGX Nasdaq
- Market Cap
- KNOP 199.5M
- CRGX 180.4M
- IPO Year
- KNOP 2013
- CRGX 2023
- Fundamental
- Price
- KNOP $6.93
- CRGX $4.07
- Analyst Decision
- KNOP
- CRGX Hold
- Analyst Count
- KNOP 0
- CRGX 7
- Target Price
- KNOP N/A
- CRGX $4.67
- AVG Volume (30 Days)
- KNOP 72.6K
- CRGX 773.9K
- Earning Date
- KNOP 03-19-2025
- CRGX 03-12-2025
- Dividend Yield
- KNOP 1.51%
- CRGX N/A
- EPS Growth
- KNOP N/A
- CRGX N/A
- EPS
- KNOP 0.18
- CRGX N/A
- Revenue
- KNOP $312,629,000.00
- CRGX N/A
- Revenue This Year
- KNOP $1.40
- CRGX $119.08
- Revenue Next Year
- KNOP $2.53
- CRGX N/A
- P/E Ratio
- KNOP $36.02
- CRGX N/A
- Revenue Growth
- KNOP 8.60
- CRGX N/A
- 52 Week Low
- KNOP $4.94
- CRGX $3.00
- 52 Week High
- KNOP $9.11
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- KNOP 74.66
- CRGX 40.37
- Support Level
- KNOP $6.53
- CRGX $3.98
- Resistance Level
- KNOP $6.84
- CRGX $4.25
- Average True Range (ATR)
- KNOP 0.22
- CRGX 0.22
- MACD
- KNOP 0.13
- CRGX 0.16
- Stochastic Oscillator
- KNOP 98.42
- CRGX 36.84
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.